Clinical Trial Search

Primary: Area Under the Concentration Time Curve of Caffeine, Omeprazole and Metoprolol in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) — 20600; 1520; 287…

Primary: Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) — 94.5; 120.2; 704.6 hours*nanomole/liters (h*nmol/l)

Primary: Sleep Quality Evaluation — 4.63; 11.75 score on a scale

Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants

Primary: 2D-SWE Measurements' Capability of Predicting Stages of Fibrosis Based on METAVIR Scoring System — NA; 96.9; 95.2; 1.00 percentage of exams

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 86.7; 88.9; 86.4; 87.0 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 84.6; 96.0; 81.0; 76.0 percentage of participants

Primary: Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS) — 8; 9 Participants

Primary: Median Total Specimen Length — 8; 14; 8; 11.5 mm

Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…

Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585

Primary: Participants With Normalized Liver Enzyme Levels — 0; 0 Participants

Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants

Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s

Primary: Biochemical: Number of Patients With Normal Transaminases at End of Treatment. — 6; 6; 6 Participants